(Bladder Cancer) FDA Approves OPDIVO
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- February 9, 2017
- Read time: 1 minute
A joint press release from Bristol-Myers Squibb (USA) and Ono Pharmaceutical (Japan) announced that Opdivo has received FDA approval for urothelial carcinoma. The release also noted that the approval covers bladder cancer patients. The eligible population includes patients with metastatic urothelial carcinoma, including bladder cancer, who have received prior platinum-based therapy and demonstrated good efficacy outcomes. This clinical trial, called CheckMate-275, enrolled 270 patients with a dosage of 3 mg/kg; the recommended dose is 240 mg, though adjustments are required based on the patient's condition and tolerability. The median age of volunteers was 66 years (range: 38–90 years); 29% of patients had received two or more prior systemic therapies. Notably, this clinical trial did not require patients to have detectable PD-L1 expression. This trial was previously presented at ESCO 2016. According to the press release, the response rate for Opdivo was 19.6%. Related information can be confirmed in the press releases from Ono Pharmaceutical and Bristol-Myers Squibb.
URL: http://www.ono.co.jp/jpnw/PDF/n17_0203.pdf
Additionally, details regarding PD-L1 detection rates from the press release are provided in the screenshots below for reference.
#BladderCancer #UrothelialCancer
- Immunotherapy
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5